You are describing **(5-hydroxy-2-phenyl-3-benzofuranyl)-(4-morpholinyl)methanone**, also known as **(5-Hydroxy-2-phenylbenzofuran-3-yl)(morpholino)methanone**. It is a chemical compound, and while it may not be widely known, it is a crucial molecule in research, specifically in the area of **pharmacology**.
Here's why it's important:
* **Potential Drug Lead:** This compound shows promising activity as a **selective inhibitor** of certain enzymes. In particular, it's been researched for its ability to inhibit **histone deacetylase (HDAC)** enzymes.
* **HDAC Inhibition:** HDAC inhibitors have emerged as potential therapeutic agents for various diseases, including cancer, neurodegenerative disorders, and inflammatory diseases. By inhibiting HDACs, this compound can potentially:
* **Modulate gene expression:** HDACs are involved in regulating gene expression. Inhibiting them can alter the expression of specific genes, leading to therapeutic effects.
* **Reduce inflammation:** HDACs are implicated in inflammatory pathways. Blocking their activity can help reduce inflammation.
* **Induce cell death in cancer cells:** HDAC inhibitors can promote apoptosis (programmed cell death) in cancer cells, making them a potential anti-cancer strategy.
* **Structure-Activity Relationship Studies:** The molecule's unique structure allows researchers to study the relationship between its chemical modifications and its biological activity. This helps scientists understand the mechanism of action and optimize its properties for therapeutic applications.
**It's important to note:** This compound is still under investigation, and it's not yet a clinically approved drug. Further research is needed to assess its safety, efficacy, and potential clinical applications.
If you are interested in learning more about this compound, you can search for it using its chemical name or related keywords like HDAC inhibitor, benzofuran derivative, or morpholine derivative in scientific databases like PubMed or Google Scholar.
| ID Source | ID |
|---|---|
| PubMed CID | 745548 |
| CHEMBL ID | 1597469 |
| CHEBI ID | 106033 |
| Synonym |
|---|
| EU-0077624 |
| CBMICRO_002540 |
| BIM-0002399.P001 |
| OPREA1_375670 |
| OPREA1_698001 |
| smr000107618 |
| MLS000111696 |
| CHEBI:106033 |
| (5-hydroxy-2-phenyl-1-benzofuran-3-yl)-morpholin-4-ylmethanone |
| STK878804 |
| (5-hydroxy-2-phenyl-1-benzofuran-3-yl)(morpholin-4-yl)methanone |
| AKOS000557930 |
| HMS2408G13 |
| CB04133 |
| smsf0018328 |
| F0308-0051 |
| 300556-78-9 |
| (5-hydroxy-2-phenylbenzofuran-3-yl)(morpholino)methanone |
| CHEMBL1597469 |
| (5-hydroxy-2-phenyl-3-benzofuranyl)-(4-morpholinyl)methanone |
| Q27183833 |
| (5-hydroxy-2-phenyl-benzofuran-3-yl)-morpholino-methanone |
| morpholine, 4-[(5-hydroxy-2-phenyl-3-benzofuranyl)carbonyl]- |
| mfcd01847180 |
| way-299433 |
| Z275118082 |
| 3-(morpholine-4-carbonyl)-2-phenyl-1-benzofuran-5-ol |
| Class | Description |
|---|---|
| benzofurans | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 22.3872 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 7.9433 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| TDP1 protein | Homo sapiens (human) | Potency | 20.5962 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 31.6228 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 3.5481 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 22.3872 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 12.5893 | 0.0200 | 10.7869 | 31.6228 | AID912 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 10.4756 | 28.1838 | AID1457 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||